The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.
Implications for Asthma Treatment Strategies in Managed Care
Comparative Effectiveness of Early Natalizumab Treatment in JC Virus-Negative Relapsing-Remitting Multiple Sclerosis
We estimated the long-term risks and benefits of disease modifying therapies. Benefits were favored by natalizumab with minimal increased risks in the negative anti-JC virus population.
Increasing Pharmaceutical Copayments: Impact on Asthma Medication Utilization and Outcomes
Even small changes in average copayment for long-term controller asthma medications can result in significant reductions in medication use and increases in healthcare services.
Managed Care Opportunities for Improving Asthma Care
